Conference themes The year 2024 has been considered the 'coming of age' era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. This part of the world is taking the ADC industry by storm with high-profile deals, multiple approvals, multiple ADCs moving into clinical trials, and novel targets being explored just to name some advancements.
Speakers: Dohyun Nam, Chairman, Professor, Aimed Bio Inc., Jinwon Jung, Senior Directory, ABL Bio, Jia He, Senior Research Analyst Targeted Therapies, Beacon and More.